Bortezomib - Allergan

Drug Profile

Bortezomib - Allergan

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Allergan
  • Class Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Multiple myeloma

Most Recent Events

  • 26 Oct 2016 Chemical structure information added
  • 20 Oct 2016 US FDA grants tentative NDA approval for Multiple myeloma
  • 22 Dec 2015 Preregistration for Multiple myeloma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top